Nasdaq · CIK 0001818794
DYN Dyne Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $16.64 on Oct 9, 2026, +19% from the 52-week low and -38% from the high.
In brief
Dyne Therapeutics, Inc. (DYN) has 126 SEC Form 4 filings on file from 8 insiders, the latest filed on Oct 6, 2026. In the last 90 days insiders made 1 open-market buy worth $40k and 9 open-market sells worth $72M, net -$72M.
90 open-market trades have been scored at DYN. The newest: Brian S Posner (director) bought $40k of stock on Oct 2, 2026, filed Oct 6, 2026, scored 32 (weak). The largest of the 50 shown: Jason P Rhodes (director) sold $65M on Aug 13, 2026, scored 55 (moderate), under a 10b5-1 plan. 3 insiders sold within 14 days of each other around Sep 8, 2026.
25 Form 144 notices of planned sales are on file, the latest filed Sep 8, 2026.
Last 90 days
Net insider value
-$72M
more sold than bought
Buys
1
$40k by 1 insider
Sells
9
$72M by 6 insiders
Insiders on file
8
with a Form 4 at this company
Price and insider trades, last year
DYNOct 9, 2026 · close 16.64
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Dyne Therapeutics, Inc., scored: the newest 50 of 90.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Brian S Posner director buy | $40k 2,500 shares | +10% | +21% from low-43% from high | |
| 30Weak | John Cox CEO & President sell | $107k 5,658 shares | -2% | - | |
| 20Weak | Douglas Kerr Chief Medical Officer sell | $116k 5,035 shares | -3% | - | |
| 15Weak | Johanna Friedl-Naderer Chief Commercial Officer sell | $25k 1,085 shares | -1% | - | |
| 31Weak | John Cox CEO & President sell | $131k 4,986 shares | -1% | +117% from low-3% from high | |
| 55Moderate | Jason P Rhodes director sell | $65M 2,586,928 shares | -64% | +117% from low-3% from high | |
| 23Weak | Erick Lucera Chief Financial Officer sell | $47k 1,797 shares | -1% | +117% from low-3% from high | |
| 16Weak | Douglas Kerr Chief Medical Officer sell | $41k 1,556 shares | -1% | +117% from low-3% from high | |
| 10Weak | Johanna Friedl-Naderer Chief Commercial Officer sell | $5,939 226 shares | -0% | +117% from low-3% from high | |
| 20Weak | Dirk Kersten director sell | $6.7M 261,460 shares | -7% | +179% from low0% from high | |
| 40Moderate | Jason P Rhodes director sell | $18M 777,451 shares | -17% | +179% from low-6% from high | |
| 40Moderate | Jason P Rhodes director sell | $11M 504,695 shares | -11% | +156% from low-14% from high | |
| 44Moderate | Erick Lucera Chief Financial Officer sell | $48k 2,362 shares | -2% | +152% from low-15% from high | |
| 35Weak | Jason P Rhodes director sell | $5.6M 267,760 shares | -5% | +148% from low-17% from high | |
| 35Weak | Dirk Kersten director sell | $5.5M 263,962 shares | -6% | +155% from low-14% from high | |
| 35Weak | Dirk Kersten director sell | $1.7M 84,355 shares | -2% | +135% from low-21% from high | |
| 27Weak | John Cox CEO & President sell | $49k 2,683 shares | -1% | +121% from low-26% from high | |
| 10Weak | Douglas Kerr Chief Medical Officer sell | $16k 887 shares | -1% | +121% from low-26% from high | |
| 10Weak | Johanna Friedl-Naderer Chief Commercial Officer sell | $2,658 145 shares | -0% | +121% from low-26% from high | |
| 37Weak | Brian S Posner director buy | $34k 2,000 shares | +9% | +106% from low-31% from high | |
| 33Weak | Brian S Posner director buy | $44k 2,500 shares | +13% | +120% from low-26% from high | |
| 33Weak | Brian S Posner director buy | $36k 2,000 shares | +11% | +122% from low-25% from high | |
| 33Weak | Brian S Posner director buy | $43k 2,500 shares | +16% | +115% from low-28% from high | |
| 27Weak | John Cox CEO & President sell | $61k 3,311 shares | -1% | +125% from low-24% from high | |
| 22Weak | Erick Lucera Chief Financial Officer sell | $27k 1,448 shares | -1% | +125% from low-24% from high | |
| 15Weak | Douglas Kerr Chief Medical Officer sell | $29k 1,564 shares | -1% | +125% from low-24% from high | |
| 10Weak | Johanna Friedl-Naderer Chief Commercial Officer sell | $4,186 228 shares | -0% | +125% from low-24% from high | |
| 35Weak | Jason P Rhodes director sell | $1.9M 106,723 shares | -7% | +117% from low-27% from high | |
| 33Weak | Jason P Rhodes director sell | $4.2M 227,337 shares | -14% | +122% from low-25% from high | |
| 33Weak | Jason P Rhodes director sell | $7.1M 384,549 shares | -22% | +131% from low-22% from high | |
| 15Weak | Dirk Kersten director sell | $219k 10,952 shares | -0% | +135% from low-21% from high | |
| 38Weak | Jason P Rhodes director sell | $16M 834,302 shares | -43% | +145% from low-18% from high | |
| 28Weak | Dirk Kersten director sell | $6.8M 337,248 shares | -7% | +150% from low-16% from high | |
| 35Weak | Dirk Kersten director sell | $2.0M 99,613 shares | -2% | +155% from low-18% from high | |
| 20Weak | Erick Lucera Chief Financial Officer sell | $107k 5,727 shares | -4% | +166% from low-25% from high | |
| 33Weak | Brian S Posner director buy | $34k 2,000 shares | +15% | +151% from low-30% from high | |
| 35Weak | Dirk Kersten director sell | $2.5M 129,672 shares | -3% | +194% from low-18% from high | |
| 33Weak | Brian S Posner director buy | $39k 2,000 shares | +17% | +194% from low-18% from high | |
| 40Moderate | Dirk Kersten director sell | $13M 688,788 shares | -13% | +160% from low-27% from high | |
| 35Weak | Brian S Posner director buy | $45k 3,000 shares | +35% | +118% from low-39% from high | |
| 26Weak | John Cox CEO & President sell | $41k 2,732 shares | -1% | +123% from low-37% from high | |
| 10Weak | Douglas Kerr Chief Medical Officer sell | $13k 904 shares | -1% | +123% from low-37% from high | |
| 10Weak | Johanna Friedl-Naderer Chief Commercial Officer sell | $2,205 148 shares | -0% | +123% from low-37% from high | |
| 27Weak | John Cox CEO & President sell | $55k 2,662 shares | -1% | +198% from low-31% from high | |
| 10Weak | Johanna Friedl-Naderer Chief Commercial Officer sell | $2,984 144 shares | -0% | +198% from low-31% from high | |
| 10Weak | Douglas Kerr Chief Medical Officer sell | $18k 880 shares | -1% | +198% from low-31% from high | |
| 26Weak | John Cox CEO & President sell | $35k 2,640 shares | -1% | +109% from low-61% from high | |
| 17Weak | Douglas Kerr Chief Medical Officer sell | $59k 4,425 shares | -5% | +94% from low-64% from high | |
| 10Weak | Johanna Friedl-Naderer Chief Commercial Officer sell | $14k 1,038 shares | -1% | +94% from low-64% from high | |
| 67Notable | John Cox CEO & President buy | $911k 100,000 shares | +70% | +31% from low-76% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 8, 2026 | Cox John Officer | 5,658 0.00% of outstanding | $107k | Sep 8, 2026 | $180k |
| Sep 8, 2026 | Kerr Douglas Officer | 35 0.00% of outstanding | $661 | Sep 8, 2026 | $148k |
| Sep 4, 2026 | Kerr Douglas Officer | 5,000 0.00% of outstanding | $122k | Sep 4, 2026 | $57k |
| Aug 14, 2026 | Atlas Venture Fund XI, LP Shareholder | 1,359,674 0.73% of outstanding | $35M | Aug 14, 2026 | none |
| Aug 14, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | 322,465 0.17% of outstanding | $8.4M | Aug 14, 2026 | none |
| Aug 14, 2026 | Atlas Venture Opportunity Fund II, LP Shareholder | 478,377 0.26% of outstanding | $12M | Aug 14, 2026 | none |
| Aug 13, 2026 | Atlas Venture Fund XI, LP Shareholder | 268,354 0.14% of outstanding | $7.0M | Aug 13, 2026 | none |
| Aug 13, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | 63,643 0.03% of outstanding | $1.7M | Aug 13, 2026 | none |
| Aug 13, 2026 | Atlas Venture Opportunity Fund II, LP Shareholder | 94,415 0.05% of outstanding | $2.5M | Aug 13, 2026 | none |
| Aug 13, 2026 | Cox John Officer | 4,986 0.00% of outstanding | $131k | Aug 13, 2026 | $49k |
| Aug 13, 2026 | Kerr Douglas Officer | 2,443 0.00% of outstanding | $64k | Aug 13, 2026 | $16k |
| Aug 13, 2026 | Lucera Erick Officer | 1,797 0.00% of outstanding | $47k | Aug 13, 2026 | $48k |
| Jul 27, 2026 | ForDyne B.V. Affiliate | 261,460 0.16% of outstanding | $6.7M | Jul 27, 2026 | $7.2M |
| Jul 7, 2026 | ATLAS VENTURE ASSOCIATES XI, L.P. Shareholder | 5,000 0.00% of outstanding | $114k | Jul 7, 2026 | none |
| Jul 7, 2026 | Atlas Venture Fund XI, LP Shareholder | 153,966 0.09% of outstanding | $3.5M | Jul 7, 2026 | none |
| Jul 7, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | 60,858 0.04% of outstanding | $1.4M | Jul 7, 2026 | none |
| Jul 7, 2026 | Atlas Venture Opportunity Fund II, LP Shareholder | 77,387 0.05% of outstanding | $1.8M | Jul 7, 2026 | none |
| Jul 6, 2026 | Atlas Venture Fund XI, LP Shareholder | 253,039 0.15% of outstanding | $5.8M | Jul 6, 2026 | none |
| Jul 6, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | 100,019 0.06% of outstanding | $2.3M | Jul 6, 2026 | none |
| Jul 6, 2026 | Atlas Venture Opportunity Fund II, LP Shareholder | 127,182 0.08% of outstanding | $2.9M | Jul 6, 2026 | none |
| Jun 29, 2026 | Atlas Venture Fund XI, LP Shareholder | 102,969 0.06% of outstanding | $2.2M | Jun 29, 2026 | none |
| Jun 29, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | 40,702 0.02% of outstanding | $852k | Jun 29, 2026 | none |
| Jun 29, 2026 | Atlas Venture Opportunity Fund II, LP Shareholder | 51,756 0.03% of outstanding | $1.1M | Jun 29, 2026 | none |
| Jun 26, 2026 | Atlas Venture Fund XI, LP Shareholder | 162,954 0.10% of outstanding | $3.4M | Jun 26, 2026 | none |
| Jun 26, 2026 | Atlas Venture Opportunity Fund I, LP Shareholder | 64,411 0.04% of outstanding | $1.3M | Jun 26, 2026 | none |
Transactions
The newest 50 of 282 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Brian S Posner director | POpen-market purchase Common Stock | +2,500 | $16.00 | $40k | 27,000 | 7 d ago |
| Sep 4, 2026 | Douglas Kerr Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -3,745 | $24.35 | $91k | 163,854 | 35 d ago |
| Sep 4, 2026 | Johanna Friedl-Naderer Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -900 | $24.35 | $22k | 153,082 | 35 d ago |
| Sep 8, 2026 | John Cox CEO & President | SOpen-market sale Common Stock10b5-1 | -5,658 | $18.88 | $107k | 357,507 | 35 d ago |
| Sep 8, 2026 | Johanna Friedl-Naderer Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -185 | $18.88 | $3,493 | 152,897 | 35 d ago |
| Sep 8, 2026 | Douglas Kerr Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,290 | $18.88 | $24k | 162,564 | 35 d ago |
| Aug 13, 2026 | Johanna Friedl-Naderer Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -226 | $26.28 | $5,939 | 153,982 | Aug 17, 2026 |
| Aug 13, 2026 | Douglas Kerr Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,556 | $26.28 | $41k | 167,599 | Aug 17, 2026 |
| Aug 13, 2026 | John Cox CEO & President | SOpen-market sale Common Stock10b5-1 | -4,986 | $26.28 | $131k | 363,165 | Aug 17, 2026 |
| Aug 13, 2026 | Erick Lucera Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -1,797 | $26.28 | $47k | 119,766 | Aug 17, 2026 |
| Aug 13, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -268,354 | $26.20 | $7.0M | 3,801,128 | Aug 17, 2026 |
| Aug 13, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -94,415 | $26.20 | $2.5M | 1,045,735 | Aug 17, 2026 |
| Aug 13, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -63,643 | $26.20 | $1.7M | 751,411 | Aug 17, 2026 |
| Aug 14, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,359,674 | $25.00 | $34M | 2,441,454 | Aug 17, 2026 |
| Aug 14, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -478,377 | $25.00 | $12M | 567,358 | Aug 17, 2026 |
| Aug 14, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -322,465 | $25.00 | $8.1M | 428,946 | Aug 17, 2026 |
| Jul 27, 2026 | Dirk Kersten director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -256,072 | $25.50 | $6.5M | 3,592,184 | Jul 29, 2026 |
| Jul 27, 2026 | Dirk Kersten director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,388 | $26.04 | $140k | 3,586,796 | Jul 29, 2026 |
| Jul 6, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -253,039 | $22.79 | $5.8M | 4,223,448 | Jul 8, 2026 |
| Jul 6, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -127,182 | $22.79 | $2.9M | 1,217,537 | Jul 8, 2026 |
| Jul 6, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -100,019 | $22.79 | $2.3M | 875,912 | Jul 8, 2026 |
| Jul 7, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -124,379 | $23.17 | $2.9M | 4,099,069 | Jul 8, 2026 |
| Jul 7, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -29,587 | $23.62 | $699k | 4,069,482 | Jul 8, 2026 |
| Jul 7, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -62,543 | $23.17 | $1.4M | 1,154,994 | Jul 8, 2026 |
| Jul 7, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -14,844 | $23.62 | $351k | 1,140,150 | Jul 8, 2026 |
| Jul 7, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -49,193 | $23.17 | $1.1M | 826,719 | Jul 8, 2026 |
| Jul 7, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -11,665 | $23.62 | $276k | 815,054 | Jul 8, 2026 |
| Jul 7, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,000 | $23.61 | $118k | 2,962 | Jul 8, 2026 |
| Jun 26, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -162,954 | $21.28 | $3.5M | 4,579,456 | Jun 30, 2026 |
| Jun 26, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -81,903 | $21.28 | $1.7M | 1,396,475 | Jun 30, 2026 |
| Jun 26, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -64,411 | $21.28 | $1.4M | 1,016,633 | Jun 30, 2026 |
| Jun 29, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -102,969 | $21.14 | $2.2M | 4,476,487 | Jun 30, 2026 |
| Jun 29, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -51,756 | $21.14 | $1.1M | 1,344,719 | Jun 30, 2026 |
| Jun 29, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -40,702 | $21.14 | $860k | 975,931 | Jun 30, 2026 |
| Jun 25, 2026 | Erick Lucera Chief Financial Officer | SOpen-market sale Common Stock | -2,362 | $20.37 | $48k | 121,563 | Jun 26, 2026 |
| Jun 23, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -77,855 | $21.13 | $1.6M | 4,805,639 | Jun 26, 2026 |
| Jun 23, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -39,131 | $21.13 | $827k | 1,510,157 | Jun 26, 2026 |
| Jun 23, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -30,774 | $21.13 | $650k | 1,106,036 | Jun 26, 2026 |
| Jun 24, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -50,530 | $21.02 | $1.1M | 4,755,109 | Jun 26, 2026 |
| Jun 24, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -25,397 | $21.02 | $534k | 1,484,760 | Jun 26, 2026 |
| Jun 24, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -19,973 | $21.02 | $420k | 1,086,063 | Jun 26, 2026 |
| Jun 25, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -12,699 | $21.10 | $268k | 4,742,410 | Jun 26, 2026 |
| Jun 25, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,382 | $21.10 | $135k | 1,478,378 | Jun 26, 2026 |
| Jun 25, 2026 | Jason P Rhodes director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -5,019 | $21.10 | $106k | 1,081,044 | Jun 26, 2026 |
| Jun 22, 2026 | Dirk Kersten director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -190,676 | $20.57 | $3.9M | 3,921,542 | Jun 24, 2026 |
| Jun 23, 2026 | Dirk Kersten director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -71,629 | $21.04 | $1.5M | 3,849,913 | Jun 24, 2026 |
| Jun 23, 2026 | Dirk Kersten director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -1,657 | $21.47 | $36k | 3,848,256 | Jun 24, 2026 |
| Jun 22, 2026 | Barry E Greene director | AGrant or award Stock option (right to buy)derivative | +57,463 | $0.00 | $0 | 57,463 | Jun 23, 2026 |
| Jun 17, 2026 | Dirk Kersten director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -37,454 | $20.14 | $754k | 4,159,119 | Jun 22, 2026 |
| Jun 18, 2026 | Dirk Kersten director | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -46,901 | $20.07 | $941k | 4,112,218 | Jun 22, 2026 |
50 of 282 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- John CoxCEO & President
- Johanna Friedl-NadererChief Commercial Officer
- Barry E Greeneceo, president, officer, director
- Douglas KerrChief Medical Officer
- Dirk Kerstendirector
- Erick LuceraChief Financial Officer
- Brian S Posnerdirector
- Jason P Rhodesdirector
Questions about DYN
Answered from the filings on this page, as of the latest one.
Are insiders buying DYN?
As of Oct 6, 2026, SEC Form 4 filings show 1 open-market buy worth $40k by 1 insider and 9 open-market sells worth $72M by 6 insiders at Dyne Therapeutics, Inc. in the last 90 days, net -$72M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade DYN on the open market?
Brian S Posner (director) bought $40k of DYN on Oct 2, 2026 and filed the Form 4 on Oct 6, 2026. InsiderTell scored 32 (weak).
How many insiders file Form 4 at Dyne Therapeutics, Inc.?
8 people have filed a Form 4 at Dyne Therapeutics, Inc., among them John Cox (CEO & President), Johanna Friedl-Naderer (Chief Commercial Officer), Barry E Greene (CEO, president and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.